Onconetix Inc (ONCO) - Net Assets
Based on the latest financial reports, Onconetix Inc (ONCO) has net assets worth $11.75 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.83 Million) and total liabilities ($3.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Onconetix Inc's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.75 Million |
| % of Total Assets | 79.21% |
| Annual Growth Rate | 17.47% |
| 5-Year Change | 989.91% |
| 10-Year Change | N/A |
| Growth Volatility | 554.69 |
Onconetix Inc - Net Assets Trend (2019–2025)
This chart illustrates how Onconetix Inc's net assets have evolved over time, based on quarterly financial data. Check Onconetix Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Onconetix Inc (2019–2025)
The table below shows the annual net assets of Onconetix Inc from 2019 to 2025. For live valuation and market cap data, see market value of Onconetix Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $15.77 Million | +64.05% |
| 2024-12-31 | $9.61 Million | +584.28% |
| 2023-12-31 | $1.40 Million | -93.73% |
| 2022-12-31 | $22.39 Million | +1447.65% |
| 2021-12-31 | $1.45 Million | -69.44% |
| 2020-12-31 | $4.73 Million | -21.08% |
| 2019-12-31 | $6.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Onconetix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13027468800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.00 | 0.00% |
| Other Comprehensive Income | $-231.03K | -1.47% |
| Other Components | $147.21 Million | 933.80% |
| Total Equity | $15.76 Million | 100.00% |
Onconetix Inc Competitors by Market Cap
The table below lists competitors of Onconetix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ausmon Resources Ltd
AU:AOA
|
$1.01 Million |
|
PHAXIAM Therapeutics S.A.
PA:PHXM
|
$1.01 Million |
|
Schroder European Reit Plc
LSE:SERE
|
$1.01 Million |
|
Gentlemens Equity S.A.
PA:MLGEQ
|
$1.02 Million |
|
BioNeutra Global Corp
V:BGA
|
$1.01 Million |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
$1.01 Million |
|
Maven Income and Growth VCT 4 PLC
LSE:MAV4
|
$1.01 Million |
|
Tres Or Resources Ltd
V:TRS
|
$1.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Onconetix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,610,555 to 15,764,627, a change of 6,154,072 (64.0%).
- Net loss of 14,032,342 reduced equity.
- Dividend payments of 409,510 reduced retained earnings.
- Share repurchases of 1,714,496 reduced equity.
- New share issuances of 21,942,855 increased equity.
- Other comprehensive income increased equity by 2,492,369.
- Other factors decreased equity by 2,124,804.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.03 Million | -89.01% |
| Dividends Paid | $409.51K | -2.6% |
| Share Repurchases | $1.71 Million | -10.88% |
| Share Issuances | $21.94 Million | +139.19% |
| Other Comprehensive Income | $2.49 Million | +15.81% |
| Other Changes | $-2.12 Million | -13.48% |
| Total Change | $- | 64.03% |
Book Value vs Market Value Analysis
This analysis compares Onconetix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.18x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.18x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $527.49 | $0.88 | x |
| 2020-12-31 | $416.28 | $0.88 | x |
| 2021-12-31 | $127.21 | $0.88 | x |
| 2022-12-31 | $1772.39 | $0.88 | x |
| 2023-12-31 | $-318.08 | $0.88 | x |
| 2024-12-31 | $85.01 | $0.88 | x |
| 2025-12-31 | $4.80 | $0.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Onconetix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -89.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1720.98%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.58x
- Recent ROE (-89.01%) is above the historical average (-149.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -13.70% | 0.00% | 0.00x | 1.01x | $-1.42 Million |
| 2020 | -33.79% | 0.00% | 0.00x | 1.02x | $-2.07 Million |
| 2021 | -236.24% | 0.00% | 0.00x | 2.13x | $-3.56 Million |
| 2022 | -59.94% | 0.00% | 0.00x | 1.18x | $-15.66 Million |
| 2023 | 0.00% | -63986.48% | 0.00x | 0.00x | $-36.85 Million |
| 2024 | -610.69% | -2325.21% | 0.09x | 2.93x | $-59.65 Million |
| 2025 | -89.01% | -1720.98% | 0.03x | 1.58x | $-15.61 Million |
Industry Comparison
This section compares Onconetix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $144,348,054
- Average return on equity (ROE) among peers: -81.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Onconetix Inc (ONCO) | $11.75 Million | -13.70% | 0.26x | $1.01 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $141.09 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-20.80 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-6.52 Million | 0.00% | 0.00x | $30.68 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $11.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.66 Billion |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other … Read more